Hot News
RNS: AstraZeneca, the manufacturer of the Covishield COVID-19 vaccine, has announced its decision to withdraw the vaccine from circulation, citing “commercial reasons.” The company stated that the vaccine is no …
AstraZeneca Withdraws COVID-19 Vaccine Due to ‘Commercial Reasons’ Read More
RNS: The prices of Covid vaccine, COVISHIELD (Serum Institute) and COVAXIN (Bharat Biotech) have been slashed for private hospitals. The price of the Covishield vaccine has been reduced from 600 …
Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals Read More
RNS: Amidst rising COVID cases in European and few Asian countries, the National Technical Advisory Group on Immunisation (NTAGI) has recommended reducing the gap between the first and second dose …
“Reduce Covishield vaccine gap” : NTAGI Read More
RNS: The subject expert committee (SEC) of Drugs controller General of India (DCGI) has recommended that Hyderabad-based Bharat Biotech can conduct phase- three trials on its intranasal vaccine. The company …
DGCI gives nod for Phase 3 trials of intranasal vaccine Read More RNS: A single dose of Covishield Vaccine administered to those recovered from the infection with SARS-CoV-2 indicated these people were more immune against Covid-19 than those who were not previously …
Single Covishield vaccine shot sufficient for recovered persons: Study Read More
RNS: ESL Steel Limited, a national steel manufacturer from the Vedanta Group, has organised a ‘Covishield’ vaccination drive for its on-roll employees. The week-long drive started from 2 June, has already …
ESL organises ‘Covishield’ vaccination drive for its on-roll employees Read More
#Bharat Biotech applies for WHO emergency use listing for Covaxin RSN: Rejecting the claims and media reports that “Vaccine Passport”— that the type of vaccine administered— will regulate international travel, …
“Vaccine Passport”: No consensus yet at WHO level Read More RNS: The government has increased the intervals between two doses of Covishield to 12 to 16 weeks from the existing 6 to 8 weeks on Thursday. This is the second …
Covishield 2nd dose interval increases to 12-16 weeks Read More
RNS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, official sources said. The trial …
Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds Read More RNS: Vaccination against COVID-19 is now being attempted to be put to all people aged above 18 years. Walk-in vaccinations are not permitted for the 18-44 age groups but booking …
Tools that help you to find COVID-19 vaccination slot: Expert Read More